Neurocrine Biosciences
NBIX
$112.50
Share price
-2.31%
Change (1 day)
19.60%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Total debt
Total debt on the balance sheet as of June 2023 : $0.25 B
According to Neurocrine Biosciences 's latest financial reports the company's total debt is $0.25 B. A company’s total debt is the sum of all current and non-current debts.
Neurocrine Biosciences - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $0.26 B | -40.3% |
| 2021-12-31 | $0.44 B | 6.82% |
| 2020-12-31 | $0.41 B | -16.79% |
| 2019-12-31 | $0.49 B | 27.54% |
| 2018-12-31 | $0.38 B | 5.11% |
| 2017-12-31 | $0.36 B | |
| 2009-12-31 | $11.53 M | |
| 2007-12-31 | $1.48 M | -97.23% |
| 2006-12-31 | $53.64 M | -9.7% |
| 2005-12-31 | $59.4 M | -10.17% |
| 2004-12-31 | $66.12 M | 81.5% |
| 2003-12-31 | $36.43 M | 359.14% |
| 2002-12-31 | $7.93 M | 39.53% |
| 2001-12-31 | $5.68 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $34.92 B | 13,395.75% | 🇺🇸 USA |
 AbbVie ABBV | $62.09 B | 23,892.66% | 🇺🇸 USA |
 Eli Lilly LLY | $18.82 B | 7,172.02% | 🇺🇸 USA |
 Repligen
RGEN | $0.42 B | 62.56% | 🇺🇸 USA |
 Athersys ATHX | $24.03 M | -90.71% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.28 B | 10.55% | 🇺🇸 USA |
 Palatin Technologies PTN | $0.79 M | -99.69% | 🇺🇸 USA |
 Royalty Pharma RPRX | $7.12 B | 2,653.65% | 🇬🇧 UK |